Online Purchasing Account You are logged on as Guest. LoginRegister a New AccountShopping cart (Empty)
United States 


AGT inhibitor
ALX-420-044-M025 25 mg 114.00 USD
ALX-420-044-M100 100 mg 392.00 USD
ALX-420-044-M500 500 mg 1,296.00 USD
Do you need bulk/larger quantities?
Antitumor and antiangiogenic compound. DNA alkylating agent. Induces G2/M arrest and apoptosis through adduction of a methyl group to O6 position of guanine in genomic DNA. Inactivates DNA repair protein O(6)-alkylguanine DNA alkyltransferase (AGT) in base excision repair (BER) pathway. Chemotherapeutic agent. Modifies drug resistance.

Product Details

Alternative Name:8-Carbamoyl-3-methylimidazo[5,1-d]-1,2,3,5-tetrazin-4(3H)-one
MI:14: 9139
Purity:≥98% (HPLC)
Appearance:White to off-white crystalline powder.
Solubility:Soluble in DMSO; slightly soluble in water.
Shipping:Ambient Temperature
Long Term Storage:-20°C
Regulatory Status:RUO - Research Use Only
Please mouse over

Product Literature References

Improved effects of honokiol on temozolomide-induced autophagy and apoptosis of drug-sensitive and -tolerant glioma cells: C.C. Chio, et al.; BMC Cancer 18, 379 (2018), Abstract; Full Text
Direct modification of the 5-HT3 receptor current by some anticancer drugs: Y. Nakamura, et al.; Eur. J. Pharmacol. 821, 21 (2017), Abstract;
Hedgehog/Gli1 signaling pathway regulates MGMT expression and chemoresistance to temozolomide in human glioblastoma: K. Wang, et al.; Cancer Cell Int. 17, 117 (2017), Abstract; Full Text
Underexpression of HOXA11 Is Associated with Treatment Resistance and Poor Prognosis in Glioblastoma: Y.B. Se, et al.; Cancer Res. Treat. 49, 387 (2017), Abstract; Full Text
Concomitant treatment of brain metastasis with whole brain radiotherapy [WBRT] and temozolomide [TMZ] is active and improves quality of life: R. Addeo, et al.; BMC Cancer 7, 18 (2007), Abstract; Full Text
Temozolomide for the treatment of metastatic melanoma: a systematic review: I. Quirt, et al.; Oncologist 12, 1114 (2007), (Review), Abstract; Full Text
Mutagenic potential of temozolomide in bone marrow cells in vivo: H. Geiger, et al.; Blood 107, 3010 (2006), Abstract; Full Text
Inhibition of angiogenesis by non-toxic doses of temozolomide: H. Kurzen, et al.; Anticancer Drugs 14, 515 (2003), Abstract;
Temozolomide induces apoptosis and senescence in glioma cells cultured as multicellular spheroids: W. Gunther, et al.; Br. J. Cancer 88, 463 (2003), Abstract;
Combined treatment with temozolomide and poly(ADP-ribose) polymerase inhibitor enhances survival of mice bearing hematologic malignancy at the central nervous system site: L. Tentori, et al.; Blood 99, 2241 (2002), Abstract; Full Text
p53 effects both the duration of G2/M arrest and the fate of temozolomide-treated human glioblastoma cells: Y. Hirose, et al.; Cancer Res. 61, 1957 (2001), Abstract; Full Text
Temozolomide: a novel oral alkylating agent: S.J. Danson & M.R. Middleton; Expert Rev. Anticancer Ther. 10, 13 (2001), Abstract;
Antitumor Imidazotetrazines. 35. New Synthetic Routes to the Antitumor Drug Temozolomide: Y. Wang, et al.; J. Org. Chem. 62, 7288 (1997), Abstract;
Temozolomide: a review of its discovery, chemical properties, pre-clinical development and clinical trials: E.S. Newlands, et al.; Cancer Treat. Rev. 23, 35 (1997), Abstract;
Antitumor imidazotetrazines--XV. Role of guanine O6 alkylation in the mechanism of cytotoxicity of imidazotetrazinones: M.J. Tisdale; Biochem. Pharmacol. 36, 457 (1987), Abstract;
Antitumor imidazotetrazines. 1. Synthesis and chemistry of 8-carbamoyl-3-(2-chloroethyl)imidazo[5,1-d]-1,2,3,5-tetrazin-4(3 H)-one , a novel broad-spectrum antitumor agent: M.F. Stevens, et al.; J. Med. Chem. 27, 196 (1984), Abstract;